Traws Pharma (TRAW) Stock Price, News & Analysis

Company Overview

Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.

Key Stats

• Today's Range: $1.53 to $1.78
• 50-Day Range: $1.14 to $2.22
• 52-Week Range: $0.97 to $3.27
• Volume: 910,594 shs
• Average Volume: 6.18 million shs
• Market Capitalization: $16.56 million
• P/E Ratio: 1.76
• Dividend Yield: N/A
• Price Target: $8.00
• Consensus Rating: Moderate Buy

Traws Pharma Stock Analysis - MarketRank™

Traws Pharma scored higher than 80% of companies evaluated by MarketBeat, and ranked 136th out of 866 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Traws Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 strong buy rating, 1 buy rating, 1 hold rating, and 1 sell rating.

Upside Potential

Traws Pharma has a consensus price target of $8.00, representing about 390.8% upside from its current price of $1.63.

Amount of Analyst Coverage

Traws Pharma has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Traws Pharma are expected to grow in the coming year, from ($2.51) to ($2.42) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Traws Pharma is 1.76, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.59.

Price to Earnings Ratio vs. Sector

The P/E ratio of Traws Pharma is 1.76, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 20.90.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.41% of the float of Traws Pharma has been sold short.

Short Interest Ratio / Days to Cover

Traws Pharma has a short interest ratio ("days to cover") of 1.78, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Traws Pharma has recently increased by 38.08%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Traws Pharma does not currently pay a dividend.

Dividend Growth

Traws Pharma does not have a long track record of dividend growth.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 0.70

News Sentiment

Traws Pharma has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Traws Pharma this week, compared to 2 articles on an average week.

Search Interest

6 people have searched for TRAW on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

MarketBeat Follows

8 people have added Traws Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 700% compared to the previous 30 days.

Company Ownership

• Score: 3.5 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $998,207.00 in company stock, which represents 6.0275% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Traws Pharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $998,207.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

14.00% of the stock of Traws Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

7.95% of the stock of Traws Pharma is held by institutions.

Company Calendar

• Last Earnings: 4/15/2026
• Today: 5/14/2026
• Next Earnings (Estimated): 5/18/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TRAW
• Previous Symbol: NASDAQ:TRAW
• CIK: 1130598
• Web: www.onconova.com
• Phone: 267-759-3680
• Fax: 267-759-3681
• Employees: 17
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Traws Pharma: $8.00
• High Price Target: $8.00
• Low Price Target: $8.00
• Potential Upside/Downside: +390.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.93
• Trailing P/E Ratio: 1.76
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $9.17 million
• Net Margins: N/A
• Pretax Margin: 328.67%
• Return on Equity: 112.18%
• Return on Assets: 35.31%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.72
• Quick Ratio: 0.72

Sales & Book Value

• Annual Sales: $2.79 million
• Price / Sales: 5.94
• Cash Flow: $0.72 per share
• Price / Cash Flow: 2.25
• Book Value: ($0.07) per share
• Price / Book: -23.29

Miscellaneous

• Outstanding Shares: 10,160,000
• Free Float: 8,735,000
• Market Cap: $16.56 million
• Optionable: No Data
• Beta: 1.47